Context Therapeutics Inc. (NASDAQ:CNTX) Given Consensus Rating of “Buy” by Brokerages

Shares of Context Therapeutics Inc. (NASDAQ:CNTX) have been given an average rating of “Buy” by the seven brokerages that are presently covering the stock, Marketbeat.com reports. Six equities research analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $6.17.

A number of analysts have weighed in on the stock. D. Boral Capital reissued a “buy” rating and set a $9.00 price objective on shares of Context Therapeutics in a report on Friday, March 21st. JMP Securities started coverage on shares of Context Therapeutics in a research note on Wednesday, January 8th. They set an “outperform” rating and a $4.00 price target on the stock. HC Wainwright reissued a “buy” rating and issued a $5.00 price target on shares of Context Therapeutics in a research report on Friday, March 21st. Finally, Citizens Jmp upgraded Context Therapeutics to a “strong-buy” rating in a research report on Wednesday, January 8th.

Institutional Investors Weigh In On Context Therapeutics

Hedge funds have recently made changes to their positions in the business. State Street Corp raised its stake in shares of Context Therapeutics by 21.5% during the third quarter. State Street Corp now owns 111,907 shares of the company’s stock worth $219,000 after purchasing an additional 19,800 shares during the last quarter. Y Intercept Hong Kong Ltd acquired a new position in Context Therapeutics in the 3rd quarter valued at $89,000. Franklin Resources Inc. purchased a new position in Context Therapeutics during the 3rd quarter worth $3,689,000. Clear Harbor Asset Management LLC lifted its stake in shares of Context Therapeutics by 60.6% in the 4th quarter. Clear Harbor Asset Management LLC now owns 57,804 shares of the company’s stock worth $61,000 after acquiring an additional 21,804 shares during the period. Finally, Geode Capital Management LLC boosted its holdings in shares of Context Therapeutics by 9.2% in the fourth quarter. Geode Capital Management LLC now owns 628,729 shares of the company’s stock valued at $661,000 after acquiring an additional 52,830 shares in the last quarter. Institutional investors and hedge funds own 14.03% of the company’s stock.

Context Therapeutics Trading Down 11.1 %

Context Therapeutics stock opened at $0.66 on Monday. The stock has a market cap of $58.77 million, a P/E ratio of -0.72 and a beta of 2.06. The company has a fifty day simple moving average of $0.83 and a 200-day simple moving average of $1.38. Context Therapeutics has a 12-month low of $0.64 and a 12-month high of $2.75.

Context Therapeutics (NASDAQ:CNTX) last released its quarterly earnings data on Thursday, March 20th. The company reported ($0.04) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.05) by $0.01. As a group, sell-side analysts forecast that Context Therapeutics will post -0.51 earnings per share for the current fiscal year.

About Context Therapeutics

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.